Beam Therapeutics, Inc.

Beam Therapeutics, Inc. has recently revised its evaluation amid changing market conditions. The stock, priced at $24.25, has seen a 5.76% return over the past year, contrasting with the S&P 500's 19.89%. Technical indicators present a mixed outlook, highlighting the company's challenges in a competitive landscape.

Beam Therapeutics, Inc. has recently revised its evaluation amid current market conditions, with its stock priced at $27.96. Over the past year, the company has achieved a return of 26.57%, outperforming the S&P 500. However, its three-year return remains negative, indicating potential volatility and risks.

Beam Therapeutics, Inc. saw a notable decline in stock price today, contrasting with the stable performance of the S&P 500. Despite recent modest gains, the company's longer-term performance reveals significant declines over three and five years, alongside challenges such as negative net profit and declining sales.

Beam Therapeutics, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock price has shown slight movement, with notable volatility over the past year. Technical indicators present mixed signals, while performance comparisons reveal significant disparities against the S&P 500 over different time frames.

Beam Therapeutics, Inc. has seen a significant stock price increase today, contrasting with a slight decline in the S&P 500. Despite recent gains, the company reported a substantial net profit loss and declining net sales, alongside negative cash flow and financial risks reflected in its operating metrics.

Beam Therapeutics, Inc. has recently revised its evaluation amid market dynamics, with its stock showing slight gains. The company has experienced significant volatility over the past year. While it has outperformed the S&P 500 in the short term, longer-term returns reveal challenges in comparison to the index.

Beam Therapeutics, Inc. has experienced notable stock price fluctuations, currently priced at $22.97. The company has shown mixed technical performance indicators, with varying trends in momentum and volume. While it has outperformed the S&P 500 over the past month, longer-term returns indicate a decline, suggesting potential strategic adjustments.

Beam Therapeutics, Inc. saw a notable increase in its stock price on September 18, 2025, reaching an intraday high. Despite recent gains and strong short-term performance, the company has struggled with negative results over the past three quarters and a modest one-year performance. Its market capitalization is around USD 2,017 million.